로딩 중…
StockDiggingStockDigging

Johnson & Johnson

JNJ· NYSE
$228.36-2.49%
2026-06-18

Price Chart

Johnson & Johnson+54.40%

Financials

※ FY = Fiscal Year

Investment Metrics(as of 2026-06-18)

MetricValue
Size
Market Cap$549.71B
Revenue$96.36B
Net Income$21.04B
Total Assets$200.89B
Net Assets$81.19B
Employees138,200
Value
P/E26.13x
P/B6.77x
P/S5.70x
EV/EBITDA17.25x
FCF Yield3.24%
Profitability
ROE25.92%
ROA10.47%
Op. Margin26.87%
Revenue Growth9.91%
Earnings Growth-52.40%
Financial Health
Debt Ratio147.45%
Total Debt$17.46B
FCF$17.80B
Cash$21.69B
Current Ratio1.03x
Net Debt/EBITDA-0.13x
Dividend
Div. Yield2.28%
Div. Growth3.80%
Performance
1Y Return54.40%
1M Return-0.71%
From 52W High-9.28%
1Y MDD-10.96%
Trading
Volume9,264,810 shares
Trading Value$2.13B
Per Share
EPS$11.04
BPS$33.58

Company Info

CEO Mr. Joaquin Duato
Employees 138,200
HQ New Brunswick, United States

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.